microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review. Front Immunol. 2024 Mar 28;15:1354613. doi: 10.33...
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Arch. 2013; 462 :39–46.Dijkstra JR, Heideman DA, Meijer GA, Boers JE, t Hart NA, Diebold J, et al. KRAS mutation analysis on low percentage of colon cancer cells: the ...
For example, in the last few years, we've observed that mutations in KRAS predict resistance to anti-EGFR therapeutics in colon cancer. Earlier this year, the US Food and Drug Administration approved the first ever KRAS inhibitor for use in patients, in this case non-small cell lung cancer...
In KRAS-mutated tumours, other oncogenes or tumour suppressor genes may also be abnormal and may participate in immune escape together with KRAS mutation. For example, in lung cancer, coactivation of KRAS (G12D) and MYC drove the aggregation of anti-inflammatory macrophages, but the absence ...
This mutation confers a poor prognosis in the metastatic setting, and a high risk of cancer recurrence as seen in several studies [6–9]. It is mutated in one-third of all cancers including colon cancer and pancreatic cancer. In addition, the three human RAS genes (NRAS, HRAS, KRAS) ...
Cyclooxygenase‑2 expression is an independent predictor of poor prognosis in colon cancer Clin. Cancer Res., 14 (2008), pp. 8221-8227 View in ScopusGoogle Scholar [27] L.M. Shafer, L.W. Slice Anisomycin induces COX-2 mRNA expression through p38(MAPK) and CREB independent of small GTPa...
Kevin M. Haigis, in Trends in Cancer, 2017 Trends KRAS is the most commonly mutated oncogene in human cancer, with particularly high frequency in cancers of the pancreas, colon, and lung. KRAS mutation is associated with poor prognosis, yet there are no effective therapies to specifically treat...
KRAS mutation testing in metastatic colorectal cancer The KRAS oncogene is mutated in approximately 35%-45% of colorectal cancers, and KRAS mutational status testing has been highlighted in recent years. The m... T Cong,D Xiang - 《World Journal of Gastroenterology》 被引量: 303发表: 2012年 ...
or microsatellite instability status, and the effect of adjuvant chemotherapy assignment on outcome did not differ according to KRAS status.Conclusions: In this large trial of chemotherapy in stage III colon cancer patients, KRAS mutational status was not associated with any significant influence on dis...
The NCCN Colon/Rectal Cancer Panel believes that RAS mutation status should be determined at diagnosis of stage IV disease. Patients with any known RAS mutation should not be treated with either cetuximab or panitumumab....